The effect of metformin in patients with ovarian cancer
Phase 3
Recruiting
- Conditions
- Serum CA125 changes.Elevated cancer antigen 125 [CA 125]R97.1
- Registration Number
- IRCT20120922010901N7
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 90
Inclusion Criteria
Confirmed ovarian epithelial cancer with pathology report
Serum cancer antigen 125 level above 35 mg/dl
Laparotomy and surgical tumor staging candidate
Exclusion Criteria
Diabetes
Gastrointestinal disorders
Kidney failure
Metformin intolerance
Having other cancers in addition to ovarian epithelial cancer
Previous history of chemotherapy
Serum cancer antigen 125 level equal and lower than 35 mg/dl
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment. Timepoint: Three months after the intervention. Method of measurement: Serum level of cancer antigen 125.
- Secondary Outcome Measures
Name Time Method